AHRQ study finds med mgmt. measures reduce adverse drug events

The latest post on the Office of the National Coordinator of Health IT’s blog, HealthIT Buzz, cites the impact EHRs can have on the rate of adverse drug events.

A study funded by the Agency for Healthcare Research and Quality (AHRQ) found Florida hospitals that adopted all five core measures of Meaningful Use for medication management in 2010 had the lowest rate of adverse drug events of all hospitals in the state.

Jon White, MD, AHRQ’s director of health IT, and Judy Murphy, RN, director of the Office of Clinical Quality and Safety and ONC’s chief nursing officer, co-authored the post.

They wrote that hospitals that identified medication management as a major concern had the highest rate of adverse drug events, followed by hospitals that had not yet adopted any of the measures.

Using CPOE, information exchange and maintaining active lists of medications and medication allergies are some of the specific medication management measures.

The study also affirmed another powerful force facing hospitals in deploying EHRs to reduce adverse drug events: physician resistance.

Hospitals where physicians objected to adopting HITECH’s meaningful use measures for medication management saw their adverse drug events increase by 14 percent, compared to a 52 percent reduction at hospitals where physicians supported the medication management meaningful use measures. Even hospitals that cited costs as a main barrier to adoption of medication management measures reduced their drug errors by 35 percent.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.